CISPLATIN INHIBITS ERYTHROID COMMITTED PROGENITOR (BFU-E) MOBILIZATION IN PERIPHERAL-BLOOD

Circulating myeloid (CFU-GM) and erythroid (BFU-E) progenitor levels w ere evaluated weekly throughout 3 courses of treatment with vinorelbin e (VNB) ifosfamide (IFO) and filgrastim (G-CSF) with or without additi on of cisplatin (DDP) in 20 stage IIIB or IV non small-cell lung cance r patients. In IFO, VNB, DDP-treated patients, BFU-E mobilization in p eripheral blood following chemotherapy and G-CSF was completely lackin g, in contrast with the patients treated with IFO, VNB plus G-CSF. CFU -GM release, however, was of the same order in the 2 groups of patient s. Further investigations are needed to explain why presence of DDP in this chemotherapeutic protocol hinders erythroid progenitor release i n peripheral blood.